NCT07674693尚未招募1 期
A Phase 1 Study to Determine the Safety and Tolerability of Whole Brain Radiotherapy (WBRT) or Proton Craniospinal Irradiation (PCSI) With Multiple Doses of Rhenium-186 NanoLiposome (186RNL, REYOBIQ) Administered Via Intraventricular Catheter for Leptomeningeal Metastases
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 29
- 主要终点
- Incidence of Dose-Limiting Toxicities (DLTs)
研究概览
简要总结
This Phase 1 study is designed to assess the safety, tolerability, and schedule feasibility of administering Rhenium-186 NanoLiposome (REYOBIQ) at different dosing intervals following whole brain radiotherapy (WBRT) or proton craniospinal irradiation (PCSI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age at screening
- •Ability to understand the purposes and risks of the study and has signed a written informed consent document approved by the site-specific IRB
- •Proven and documented LM evidenced by positive CSF cytology or CSF circulating tumor cells, from any primary solid tumor
- •Patients may have received prior chemotherapy regimens and prior radiation (there is no limit)
- •Karnofsky performance status of 60 to 100
- •Acceptable liver function:
- •Bilirubin ≤ 1.5 times upper limit of normal
- •AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal for subjects with normal liver
- •AST (SGOT) and ALT (SGPT) ≤ 5.0 times upper limit of normal for subjects with liver metastasis
- •Subjects with a creatinine clearance greater than or equal to 60 mL/min (using the Cockcroft-Gault Equation) for males and females.
- •Acceptable hematologic status (without hematologic support):
- •ANC ≥ 1000 cells μL
- •Platelet count ≥ 75,000/μL
- •Hemoglobin ≥ 9.0 g/dL
- •PT/INR and PTT ≤1.5 x ULN, unless treated with anticoagulants
- •All women of childbearing potential must have a negative serum pregnancy test at screening. Male and female subjects must agree to use effective means of contraception (for example, surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose.
排除标准
- •The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v6.0) Grade ≤ 1 from AEs due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study. Prior AEs due to alopecia, anemia, and lymphopenia are not required to be recovered to Grade ≤ 1 prior to 186RNL treatment, assuming other inclusion criteria are satisfied.
- •Ventriculo-peritoneal or ventriculo-atrial shunts or contraindications to placement of Ommaya reservoir.
- •Females of childbearing potential who are pregnant, breast feeding, or may possibly be pregnant without a negative serum pregnancy test (see inclusion criteria).
- •Serious intercurrent illness, clinically significant cardiac arrhythmias, uncontrolled systemic infection, symptomatic congestive heart failure or unstable angina pectoris within 3 months prior study drug, myocardial infarction, stroke, transient ischemic attack within 6 months, seizure disorder with any seizure occurring within 14 days prior to consenting or encephalopathy.
- •Active severe non hematologic organ dysfunction such as renal, cardiac, hepatic, pulmonary, or gastrointestinal grade 3 or above.
- •Toxicity from prior treatments (grade 3 or above) that have not subsided to grade
- •Patients with prior CNS directed EBRT.
- •Cytotoxic systemic therapy is excluded if given within 14 days or 5 half-lives, whichever is shorter, prior to 186RNL treatment. Small-molecule kinase inhibitors, targeted therapies, immunotherapy, and hormonal therapy can be given up to the day of treatment per investigator discretion.
- •Projected survival of less than 60 days.
研究组 & 干预措施
WBRT or PCSI followed by REYOBIQ
Experimental
Patients will undergo WBRT or PCSI; following WBRT or PCSI, patients will initiate REYOBIQ in 28 (+/- 7 days) days following a dose escalation scheme.
干预措施: 186RNL (Drug)
结局指标
主要结局
Incidence of Dose-Limiting Toxicities (DLTs)
时间窗: Up to Month 13 (28 Days Post-Final Dose)
The incidence of DLTs during the 28-day DLT window following any administration of REYOBIQ.
次要结局
- Central Nervous System Progression-Free Survival (CNS PFS)(Up to Year 5)
- Overall Survival (OS)(Up to Year 5)
- Overall Response Rate (ORR)(Up to Year 5)
- Duration of Response (DoR)(Up to Year 5)
研究者
相似试验
招募中
2 期
Phase 1b Study to Assess the Safety, Tolerability and Pharmacodynamics of PBFT02 in Adult Participants with Frontotemporal Dementia (FTD) and GRN or C9orf72 Mutations2023-507724-23-00Passage Bio Inc.4
撤回
1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a pDNA Vaccine Candidate Against COVID-19 in Healthy Adults2023-505135-12-00Imam Abdulrahman Bin Faisal University60
招募中
1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors2022-501684-40-00Gilead Sciences Inc.93
招募中
1/2 期
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma2022-501686-47-00Galapagos, Galapagos25
招募中
1 期
Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors2023-509688-25-00Pharma Mar S.A.50